Differences between primary peritoneal serous carcinoma and advanced serous ovarian carcinoma: a study based on the SEER database

Abstract Objective This study aimed to compare clinical features and overall survival (OS) between patients with primary peritoneal serous carcinoma (PPSC) and those with advanced serous ovarian carcinoma (ASOC) and to identify prognostic factors. Methods Patients diagnosed with PPSC and ASOC from 2010 to 2015 from the Surveillance, Epidemiology, and End Results (SEER) database were enrolled. Pearson’s chi-square test was used to compare clinical features. The primary endpoint was OS. The Kaplan–Meier method and log–rank test were used to perform the survival analysis. Propensity score matching was also conducted. Univariate, multivariate and subgroup analyses were performed using the Cox proportional hazards model. Results A total of 708 PPSC patients and 7610 ASOC patients were enrolled. The clinical features of PPSC patients were noticeably different from those of ASOC patients. The survival analysis showed that PPSC patients had poorer outcomes than ASOC patients. Even after the clinical features were balanced, PPSC patients still had poorer survival. Univariate and multivariate analyses indicated that older age, higher tumor grade and advanced American Joint Committee on Cancer stage were adverse prognostic factors in both groups, while surgery and chemotherapy were protective factors. A subgroup analysis demonstrated that most factors favored ASOC patients. The total distant metastasis rates of PPSC and ASOC were similar. Liver or lung metastasis was common, but bone and brain metastases were rare. A higher proportion of liver metastasis was observed in the ASOC group. Conclusion The clinical features and survival outcomes between PPSC patients and ASOC patients are clearly different, and PPSC is more aggressive than ASOC.

Download Full-text

Clinicopathologic features and survival outcomes of signet cell carcinoma of the appendix: Analysis of the SEER database.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e16147 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e16147-e16147

Author(s):

Kamelah Abushalha ◽

Wa'el Tuqan ◽

Sara Albagoush ◽

Sawsan Abulaimoun ◽

Peter T. Silberstein

Keyword(s):

Cell Carcinoma ◽

Proportional Hazards Model ◽

Total Colectomy ◽

Cox Proportional Hazards ◽

Cox Proportional Hazards Model ◽

Rank Test ◽

Bivariate Analysis ◽

Seer Database ◽

Cancer Specific Survival ◽

Factors Associated

e16147 Background: Signet ring cell carcinoma of the appendix (SRCCA) is an exceedingly rare tumor, and limited data are available on the characteristics and survival probabilities of this tumor. Methods: Surveillance, Epidemiology, and End Results (SEER) database was used to identify 527 patients diagnosed with SRCCA between 2000 and 2015. The database was used to examine demographic information. Survival analysis was made by Kaplan-Meier and compared by log-rank test. Cox proportional hazards model was adopted for prognostic variable evaluation. Results: The majority of SRCCA patients were female (63.9%) and white (83.8%), with a mean age at diagnosis of 56 years. Histologically; 60% of the tumors were of high grade (poorly-differentiated and undifferentiated). The majority of patients were diagnosed with metastatic disease (61.3%) and received surgical treatment (86.5%), with sub-total colectomy was the most common surgery performed (45.6%). Median overall survival was 26 months, with a cancer-specific survival at three-year and five-years of 39% and 18.4%, respectively. There was a 10-year difference in median survival time based on sex (females vs males; 23 vs 33 months respectively). On bivariate analysis; factors associated with significantly increased mortality (p < 0.05), include increased age (HR 1.02), female gender (HR 1.33), AJCC T category (T4 compared to T0; HR 1.96), AJCC N category (N1 compared to N0; HR 1.9) and AJCC M category (M1 compared to M0: HR 2.62). Factors associated with improved survival (p < 0.05) included treatment by surgical resection; total colectomy (HR 0.47) and sub-total colectomy (HR 0.45) . Conclusions: This is the largest study to date on SRCCA. Older white females are most commonly affected and often diagnosed at advanced stage and grade.

Download Full-text

Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.5042 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. 5042-5042

Author(s):

S. Patil ◽

R. A. Figlin ◽

T. E. Hutson ◽

M. D. Michaelson ◽

S. Négrier ◽

...

Keyword(s):

Overall Survival ◽

Prognostic Factors ◽

Proportional Hazards ◽

Proportional Hazards Model ◽

Progression Free Survival ◽

Cox Proportional Hazards ◽

Cox Proportional Hazards Model ◽

Rank Test ◽

Type I ◽

First Line

5042 Background: Sunitinib demonstrated superior progression-free survival (PFS; the primary endpoint) over interferon-alfa (IFN-α) as first-line mRCC therapy (NEJM 2007;356:115). Median overall survival (OS) with sunitinib compared to IFN-α was: 26.4 vs. 21.8 months (HR=0.821; P=0.051 by unstratified log-rank test; Proc ASCO 2008;26, May 20 suppl; abstr 5024). An analysis of prognostic factors for OS was performed on data from this trial. Methods: 750 treatment-naïve mRCC patients were randomized 1:1 to receive sunitinib or IFN-α. By Cox proportional hazards model, selected pretreatment variables were evaluated univariately and in a multivariate model for each treatment arm. Multivariate models for each treatment arm were based on a stepwise algorithm with a type I error of 0.25 for entry and 0.15 for elimination. Further elimination was applied to identify variables significant at P<0.05. Results: In multivariate analysis of sunitinib patients, factors associated with longer OS include: interval from diagnosis to treatment ≥1 yr, ECOG PS of 0, lower corrected calcium, absence of bone metastases, lower lactic dehydrogenase (LDH), and higher hemoglobin (Hgb) ( table ). For the IFN-α treatment arm, male gender, absence of bone or lymph node metastases, lower LDH, higher Hgb, lower corrected calcium, higher neutrophil count, and interval from diagnosis to treatment ≥1 yr were associated with longer OS. Conclusions: For patients in the sunitinib treatment arm, prognostic factors identified were similar to the factors previously identified in the MSKCC risk groups (J Clin Oncol 2002;20:289). Additional prognostic factors were identified for the IFN-α arm. Further studies are warranted to independently validate these findings as well as to identify tumor-specific prognostic factors. [Table: see text] [Table: see text]

Download Full-text

High Tissue TLR5 Expression Predicts Better Outcomes in Colorectal Cancer Patients

Oncology ◽

10.1159/000516543 ◽

2021 ◽

pp. 1-12

Author(s):

Ines Beilmann-Lehtonen ◽

Jaana Hagström ◽

Harri Mustonen ◽

Selja Koskensalo ◽

Caj Haglund ◽

...

Keyword(s):

Colorectal Cancer ◽

Survival Analysis ◽

Prognostic Value ◽

Proportional Hazards Model ◽

Cox Proportional Hazards Model ◽

University Hospital ◽

Rank Test ◽

Multivariate Survival ◽

Log Rank Test ◽

Molecular Patterns

Background: Colorectal cancer (CRC), the third most common cancer globally, caused 881,000 cancer deaths in 2018. Toll-like receptors (TLRs), the primary sensors of pathogen-associated molecular patterns and damage-associated molecular patterns, activate innate and adaptive immune systems and participate in the development of an inflammatory tumor microenvironment. We aimed to explore the prognostic value of TLR3, TLR5, TLR7, and TLR9 tissue expressions in CRC patients. Methods: Using immunohistochemistry, we analyzed tissue microarray samples from 825 CRC patients who underwent surgery between 1982 and 2002 at the Department of Surgery, Helsinki University Hospital, Finland. After analyzing a pilot series of 205 tissue samples, we included only TLR5 and TLR7 in the remainder of the patient series. We evaluated the associations between TLR5 and TLR7 tissue expressions, clinicopathologic variables, and survival. Using the Kaplan-Meier method, we generated survival curves, determining significance using the log-rank test. Univariate and multivariate survival analyses relied on the Cox proportional hazards model. Results: The 5-year disease-specific survival was 55.9% among TLR5-negative (95% confidence interval [CI] 50.6–61.2%) and 61.9% (95% CI 56.6–67.2%; p = 0.011, log-rank test) among TLR5-positive patients. In the Cox multivariate survival analysis adjusted for age, sex, stage, location, and grade, positive TLR5 immunoexpression (hazard ratio [HR] 0.74; 95% CI 0.59–0.92; p = 0.007) served as an independent positive prognostic factor. TLR7 immunoexpression exhibited no prognostic value in the survival analysis across the entire cohort (HR 0.97; 95% CI 0.78–1.20; p = 0.754) nor in subgroup analyses. Conclusions: We show for the first time that a high TLR5 tumor tissue expression associates with a better prognosis in CRC patients.

Download Full-text

Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study

PeerJ ◽

10.7717/peerj.6539 ◽

2019 ◽

Vol 7 ◽

pp. e6539 ◽

Cited By ~ 3

Author(s):

Ling Cao ◽

Zhi-wen Li ◽

Min Wang ◽

Ting-ting Zhang ◽

Bo Bao ◽

...

Keyword(s):

Prognostic Factors ◽

Neuroendocrine Carcinoma ◽

Proportional Hazards Model ◽

Wedge Resection ◽

Large Cell ◽

Clinicopathological Characteristics ◽

Large Cell Neuroendocrine Carcinoma ◽

Cox Proportional Hazards Model ◽

Rank Test ◽

Ajcc Stage

Background This study was designed to investigate the clinicopathological characteristics, treatment and survival of patients with pulmonary large cell neuroendocrine carcinoma (LCNEC). Methods The Surveillance, Epidemiology and End Results database was utilized to identify patients diagnosed with pulmonary LCNEC between 2004 and 2013. Kaplan–Meier analysis was conducted to determine the overall survival (OS) and cancer-specific survival (CSS) rate. Univariate survival analysis along with log-rank test, and Cox proportional hazards model were employed to detect independent prognostic factors. Results Pulmonary LCNEC accounted for 0.58% (2972/510607) of the total number of lung and bronchus carcinoma. And a total of 1,530 eligible cases were identified, with the median follow-up time of 11 months. To be specific, the 3-, 5-year OS and CSS rates were 22.8%, 16.8% and 26.5%, 20.8% respectively. Generally, pulmonary LCNEC was commonly detected in the elderly (72.2%), males (55.9%), the upper lobe (62.0%) and advanced AJCC stage (65.5%). Multivariate analysis revealed that elderly [(≥60 and <80 years) HR:1.203, 95% CI [1.053–1.375], P = 0.007; (≥80 years) HR:1.530, 95% CI [1.238–1.891], P < 0.001] and advanced AJCC stage [(stage III) HR:2.606, 95% CI [2.083–3.260], P < 0.001; (stage IV) HR:4.881, 95% CI [3.923–6.072], P < 0.001] were independent unfavorable prognostic factors, and that female (HR:0.845, 95% CI [0.754–0.947], P = 0.004)), surgery [(Segmentectomy/wedge resection) HR:0.526, 95% CI [0.413–0.669], P < 0.001; (Lobectomy/Bilobectomy) HR:0.357, 95% CI [0.290–0.440], P < 0.001;(Pneumonectomy) HR:0.491, 95% CI [0.355–0.679], P < 0.001] , chemotherapy (HR:0.442, 95% CI [0.389–0.503], P < 0.001) and radiation (HR:0.837, 95% CI [0.738–0.949], P = 0.005) were independent favorable prognostic factors. Conclusion To sum up, age at diagnosis, sex, AJCC 8th edition stage, surgery, chemotherapy and radiation were significantly associated with OS of patients with pulmonary LCNEC.

Download Full-text

Cox Proportional Hazards Model for Identification of the Prognostic Factors in the Survival of Acute Liver Failure Patients in India

Nepalese Journal of Statistics ◽

10.3126/njs.v2i0.21155 ◽

2018 ◽

Vol 2 ◽

pp. 53-74

Author(s):

Shankar Prasad Khanal ◽

V. Sreenivas ◽

S.K. Acharya

Keyword(s):

Survival Analysis ◽

Prognostic Factors ◽

Liver Failure ◽

Cerebral Edema ◽

Goodness Of Fit ◽

Proportional Hazards ◽

Proportional Hazards Model ◽

Cox Proportional Hazards ◽

Cox Proportional Hazards Model ◽

Hazards Model

Background: Acute Liver Failure (ALF) is a kind of dangerous rare liver injury among all liver diseases. Different statistical methods such as Logistic regression, Kaplan-Meier estimate of survival function followed by Log-rank test and semi-parametric approaches of survival analysis has been applied in order to identify the significant risk factors of ALF patients. In most of the studies, regression models used in this setup has not been evaluated by model assumptions and their goodness of fit tests.Objective: To apply appropriate survival analysis technique to identify the prognostic factors in the survival of ALF patients, to develop prognostic index, and to predict survival probability for different scenario.Materials and Methods: The study is based on the retrospective cohort study design with altogether 1099 ALF patients taken from the liver clinic, All India Institute of Medical Sciences, New Delhi India. Cox regression has been considered as the suitable model for handling this time to event data, and the assumptions of the model, goodness of fit of the model was assessed and survival probabilities were predicted.Results: This study has identified six prognostic factors namely age, prothrombin time, cerebral edema, total serum bilirubin, serum creatinine and etiology for ALF patients. The hazards of mortality [HR: 2.38; 95% C.I.: (1.99, 2.85), p < 0.001] is the highest for cerebral edema among all these prognostic factors. Nearly 9%, 26%, 39%, 50%, 59% and 63% of ALF patients with a PI of 1, 3, 5, 7, 9 and 10 respectively die by 3 days of hospital stay.Conclusion: The developed Cox Proportional Hazards model with six prognostic factors has satisfied the model assumptions and goodness of fit tests. The risk score and the predicted survival probabilities will be immensely helpful to the hepatologists to make a quick decision regarding the likely prognosis of a patient at admission and helpful in triaging the ALF patients for liver transplant.Nepalese Journal of Statistics, Vol. 2, 53-74

Download Full-text

Radiation Therapy Improves Survival Outcome in Pancreatic Adenocarcinoma: Comparison of a 15-Year Institutional Experience at the University of Nebraska Medical Center with SEER Data

Journal of Radiotherapy ◽

10.1155/2014/708317 ◽

2014 ◽

Vol 2014 ◽

pp. 1-6

Author(s):

Michael J. Baine ◽

Chi Lin

Keyword(s):

Radiation Therapy ◽

Prognostic Factors ◽

Pancreatic Adenocarcinoma ◽

Proportional Hazards Model ◽

Cox Model ◽

Medical Center ◽

Cox Proportional Hazards Model ◽

Seer Database ◽

Nebraska Medical ◽

Seer Data

Objectives. We examined the role of radiation therapy (RT) in pancreatic adenocarcinoma (PA) treatment through a 15-year retrospective analysis of patients treated at University of Nebraska Medical Center (UNMC) as well as those from the SEER database. Methods. A total of 561 patients diagnosed with PA at UNMC between 1995 and 2011 and 60,587 patients diagnosed between 1995 and 2009 from the SEER were included. Examined prognostic factors for overall survival (OS) were age, gender, race, stage, year of diagnosis, and treatment with surgery, chemotherapy (CT), or RT. Time to death was plotted by Kaplan-Meier method. A Cox proportional hazards model was used to evaluate prognostic factors for OS. Results. The median OS was 7.3 and 5 months for patients from UNMC and the SEER database, respectively. A Cox model of patients from UNMC showed that RT was associated with improved OS (HR 0.77, P=0.018) after adjusting for factors including age, race, gender, stage, year of diagnosis, having surgery, or having CT. Cox analysis of patients from the SEER showed similar results (HR 0.65, P<0.0001). Conclusions. RT confers an independent survival advantage in patients being treated for PA which is apparent both at UNMC and through SEER data.

Download Full-text

Skeletal system as a rare metastatic site in patients with ovarian carcinoma

International Journal of Gynecological Cancer ◽

10.1136/ijgc-2021-002486 ◽

2021 ◽

pp. ijgc-2021-002486

Author(s):

Naziye Ak ◽

Yagmur Minareci ◽

Pinar Saip

Keyword(s):

Ovarian Cancer ◽

Multivariate Analysis ◽

Prognostic Factors ◽

Bone Metastasis ◽

Bone Metastases ◽

Proportional Hazards Model ◽

Clear Cell ◽

Cox Proportional Hazards ◽

Cox Proportional Hazards Model ◽

Rank Test

ObjectiveTo evaluate the frequency and predictors of bone metastasis in patients with ovarian cancer and to determine prognostic factors associated with this finding.MethodsPatients diagnosed with ovarian cancer between January 2009 and December 2019 were evaluated. Patients with radiologically or pathologically confirmed bone metastasis were included in the study. Survival was analyzed using Kaplan-Meier curves and compared using the log-rank test. Multivariate analysis of prognostic factors related to survival was performed using the Cox proportional hazards model.ResultsNineteen (2.6%) of 736 patients had bone metastases. Patients with clear cell histology had a higher risk of bone metastases than patients with the other epithelial histology groups (12.3% vs 2.1%, p<0.001). Overall survival was significantly lower in patients diagnosed with bone metastasis at the time of cancer diagnosis than in those diagnosed with bone metastasis during the course of the disease (median 63 vs 6.1 months, p<0.001). However, when the survival time after the development of bone metastasis was examined, no difference was found between patients with metastasis at the time of diagnosis and at the time of first or later progression (median 13.6 vs 4 months, p=0.09). In addition, the median survival of patients with clear cell histology after bone metastasis did not differ statistically from that of patients with other epithelial histology (median 22 vs 7.5 months; p=0.13). In the clear cell subgroup, bone metastasis was an independent prognostic factor for survival after multivariate analysis. For all patients, the stage at diagnosis and serum CA125 and alkaline phosphatase levels at the time of bone metastasis were prognostic factors for survival.DiscussionBone metastasis is rare in patients with ovarian cancer. However, the risk of bone metastasis is highest in patients with clear cell histology.

Download Full-text

Is Primary Tumor Excision and Specific Metastases Sites Resection Associated With Improved Survival in Stage Ⅳ Colorectal Cancer? Results From SEER Database Analysis

The American Surgeon ◽

10.1177/0003134820919729 ◽

2020 ◽

Vol 86 (5) ◽

pp. 499-507

Author(s):

Chenghao Yi ◽

Jinpeng Li ◽

Fuxin Tang ◽

Zhikun Ning ◽

Huakai Tian ◽

...

Keyword(s):

Colorectal Cancer ◽

Primary Tumor ◽

Proportional Hazards Model ◽

Lung Metastases ◽

Multivariable Analysis ◽

Stage Iv ◽

Cox Proportional Hazards Model ◽

Rank Test ◽

Seer Database ◽

Metastatic Lesions

Objective We aimed to explore the prognostic value of primary tumor and specific metastases excision on survival among patients with stage IV colorectal cancer (CRC) in the Surveillance, Epidemiology, and End Results (SEER) database. Methods Patients with stage IV CRC were selected using SEER database between 2010 and 2013. Survival rate was calculated according to the Kaplan-Meier method, and differences between curves were tested by the log-rank test. Cox proportional hazards model was used in the multivariable analysis. Results Included in this study were 27 878 patients with distant metastatic CRC. Among the single organ site of metastatic CRC, patients with solitary metastasis of lung showed the highest median overall survival (OS). Both primary and metastatic sites surgical resection for patients with liver, lung, and simultaneous liver and lung metastases had better median OS. Age younger than 65 years, Asian and Pacific Islander, distal colon and rectum, and palliative primary tumor and metastatic lesions resection were associated with better OS after multivariate analysis. Palliative primary tumor and metastatic lesions resection had a significant survival benefit compared with nonsurgical group in selected patients. Conclusion These findings support the use of preemptive surgery in the management of highly selected metastatic CRC patients.

Download Full-text

Prognostic factors for survival after embolization of hepatic metastases in uveal melanoma

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.8562 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 8562-8562 ◽

Cited By ~ 1

Author(s):

A. Yamamoto ◽

I. Chervoneva ◽

K. Sullivan ◽

D. Eschelman ◽

C. Gonsalves ◽

...

Keyword(s):

Prognostic Factors ◽

Uveal Melanoma ◽

Proportional Hazards Model ◽

Cox Model ◽

Hepatic Metastases ◽

Cox Proportional Hazards Model ◽

Gelatin Sponge ◽

Rank Test ◽

First Choice ◽

Melanoma Patients

8562 Background: Liver is the most common site of metastasis (>80%) in patients with uveal melanoma. Embolization of the hepatic artery has been used to control hepatic metastases. Methods: Uveal melanoma patients with hepatic metastases embolized with iodized poppy seed oil and gelatin sponge, and either BCNU (chemoembolization, CE) or GM-CSF (immunoembolization, IE) during periods when each of these drugs was the agent of first choice, were evaluated. Prognostic factors that predict OS and progression free survival (PFS) in the liver (PFS-L) and in the extra-hepatic systemic organs (PFS-S) were analyzed univariately using the log-rank test and multivariately using Cox proportional hazards model. The following parameters were evaluated: age, gender, pre-existing extrahepatic metastases (EHM), LDH, AST, ALP, and treatment modality (CE or IE). Results: A total of 53 uveal melanoma patients with < 50% liver involvement with melanoma were analyzed. In comparison to the 19 patients (14 males/5 females) who underwent CE, the 34 patients who underwent IE (12 males/22 females) have significantly better OS (14.1 vs. 9.7 months, p=0.012) and PFS-S (10.2 vs. 4.8 months, P=0.013) in univariate analyses. Female patients outlived male patients (14.2 vs. 9.7 months, p=0.005). In Cox model, the shorter OS was associated with male gender (hazard ratio (HR)=2.1; 95% CI, 1.1–4.0; p=0.020), and marginally related to EHM (HR=1.8; 95% CI, 1.0–3.4; p=0.052). Independent predictors of shorter PFS-S included older age (HR=1.04 per year; 95% CI: 1.01–1.06; p=0.007), EHM (HR=2.1; 95% CI, 1.1–3.8; p=0.017), and CE (HR=2.1; 95% CI, 1.2–3.8; p=0.012). The gender-by-treatment interaction was also considered in all Cox models, but it was not significant. None of the covariates was a predictor of PFS-L in univariate or multivariate analyses. Conclusions: IE and female gender were found to be positive prognostic factors for survival after embolization of hepatic metastases. No significant financial relationships to disclose.

Download Full-text

Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET).

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.4014 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. 4014-4014 ◽

Cited By ~ 3

Author(s):

James C. Yao ◽

John D. Hainsworth ◽

Edward M. Wolin ◽

Marianne E. Pavel ◽

Eric Baudin ◽

...

Keyword(s):

Multivariate Analysis ◽

Prognostic Factors ◽

Proportional Hazards Model ◽

Performance Status ◽

Univariate Analysis ◽

Primary Site ◽

Cox Proportional Hazards Model ◽

Bone Involvement ◽

Phase Iii ◽

Rank Test

4014 Background: In this large phase III trial, median progression-free survival (PFS) improved by 5.1 mo with E+O compared to P+O in patients (pts) with NET associated with carcinoid syndrome. Baseline imbalances including WHO performance status (PS) and primary site favoring P+O confounded primary analysis. Chromogranin A (CgA) and 5-hydroxyindoleacetic acid (5-HIAA) are important biomarkers in NET. Analyses were performed to identify prognostic factors and adjust for baseline imbalances. Methods: Pts were randomized to E+O (n=216) or P+O (n=213). Potential prognostic factors including baseline CgA (≤2×ULN vs >2×ULN), baseline 5-HIAA (≤median vs >median at baseline), age (<65 vs ≥65), gender, race, WHO PS (0 vs 1, 2), primary site (lung vs other), prior somatostatin analog use (yes vs no), duration from diagnosis (<6 mo, 6-24 mo, 2-5 yr, >5 yr), and organs involved (liver, bone) were assessed in univariate analysis using the log rank test and stepwise regression using Cox proportional hazards model. Results: Median PFS (mo) was significantly longer for pts with nonelevated CgA (27 vs 11; p<.001) and nonelevated 5-HIAA (17 vs 11; p<.001). Analyses also indicated age (14 vs 12; p=.01), WHO PS (17 vs 11; p=.004), liver involvement (14 vs not reached; p=.02), bone metastases (8 vs 15; p<.001), and lung as primary site (11 vs 14; p=.06) as potentially prognostic. Multivariate analysis indicated that significant prognostic factors for PFS included baseline CgA (HR, 0.47; CI, 0.34-0.65; p<.001), WHO PS (HR, 0.69; CI, 0.52-0.90; p=.006), bone involvement (HR, 1.52; CI, 1.06-2.18; p=.02), and lung as primary site (HR, 1.55; CI, 1.01-2.36; p=.04). Adjusted for covariates, a 38% reduction in risk of progression was observed for E+O (HR, 0.62; 95% CI, 0.51-0.87; p=.003). Conclusions: In the phase III RADIANT-2 trial, baseline CgA levels, WHO PS, lung as primary site, and bone involvement were important prognostic factors. Exploratory analysis adjusted for these prognostic factors indicated significant benefit of everolimus therapy.

Download Full-text